Positron emission tomography (PET) is a valuable tool in CNS and oncology research studies to measure brain functionality and metabolism. Increasingly, PET is also used to monitor metabolic activity in brain tumors. PET imaging can be performed with CT to get combined data on radioligand accumulation and anatomic localization.
Charles River’s expertise with PET and SPECT imaging and associated ex vivo techniques, provide a comprehensive state-of-the-art toolkit to evaluate the pathophysiology and drug effects in animal models of neurological disease. Access to a cyclotron in close vicinity can be used to produce short-lived positron-emitting isotopes suitable for PET imaging. In addition, arterial input function (AIF) can be generated to quantify target area concentration that is normalized to cumulative arterial radioligand concentration from the time of injection until the end of the scan.
Need help planning your PET study?
We validate targets, study drug candidates and develop new PET radiotracers. The enhanced PET imaging data can be combined with behavioral and biochemical readouts to provide translational preclinical data to support more optimally designed clinical trials that include PET imaging as a readout.